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Introduction
The classic form of chronic inflammatory demyelinating 
polyneuropathy (CIDP) is symmetrical damage of motor 
and sensory nerves; motor involvement is greater than sen-
sory [1]. The mechanism of nerves damage is presumed to 
be immune mediated [2]. Recent epidemiologic data have 
shown that up to 35% of CIDP patients may have only sen-
sory symptoms [3, 4]. 
Several clinical variants of CIDP have been reported 
widening the spectrum of this neuropathy. According to 
the European Federation of Neurological Societies (EFNS) 
and Peripheral Nerve Society (PNS) guideline (EFNS / PNS, 
revised in 2010) CIDP can be classified into two clinical 
forms: typical CIDP and atypical CIDP [5].
Atypical forms can be classified according to the clinical 
manifestations in 4 major groups: pure motor, pure sensory, 
multifocal and of distal symmetrical impairment [6,7]. The 
diagnostic criteria for these forms are however not well de-
fined possibly explaining their variable frequency ranging 
from 1% to 49% in different series and the reported differ-
ences in their treatment response [8,9]. 
A recent study fulfilled in USA showed that the majority 
of community neurologists had familiarity with the clini-
cal presentations of typical CIDP, but many thought that 
atypical phenotypes were more various than what have been 
described in guidelines [10]. The aim of this study was to 
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Abstract
Background: There are still not enough data on clinical and laboratory peculiarities of atypical chronic inflammatory demyelinating polyneuropathy 
(CIDP), ranging from only sensitive symptoms without weakness to asymmetric motor deficit. Recent epidemiological data do not clearly elucidate the 
percentage of cases with atypical CIDP from total CIDP types. Nerves conduction study, the gold standard in diagnosing demyelinating polyneuropathies 
has low sensibility for atypical forms of CIDP. The purpose of this study was determining the criteria for clinical and laboratory diagnosis of atypical 
sensory CIDP.
Material and methods: Two groups of study were identified: 30 patients with typical CIDP and 30 patients with atypical CIDP. All patients underwent 
nerves conduction studies, blood was drawn for biochemical tests, also electrophoresis and serum protein immunofixation were done. Fibular nerve 
biopsy was performed in 9 patients. Overall Neuropathy Limitation Scale (ONLS) questionnaire was used for the assessment of functional disability.
Results: Nerves conduction studies in cases with sensory CIDP show normal motor conduction velocity in 10 cases, and diminished only in 4 cases. 
Total ONLS in patients with sensory CIDP is equal to 1.85 ± 0.21 points compared to total 4.17 ± 0.240 points in patients with typical CIDP (p <0.001).
Conclusions: Nerves conduction study is not a gold standard for diagnosis atypical sensory CIDP. According to functional scores results, sensory CIDP 
is less disabling compared with typical CIDP.
Key words: sensory CIDP, demyelination, functional tests, polyneuropathy.
underline the clinical and paraclinical pecularities of pure 
sensory CIDP.
Nerve conduction studies (NCS), the gold standard in 
diagnosing demyelinating polyneuropathies, have low sen-
sitivity for atypical forms of CIDP, that’s why it’s necessary 
to identify new ways of diagnosis [11]. Often the clinical 
picture of a sensory CIDP can simulate idiopathic axonal 
polyneuropathy, losing opportunity of proper immuno-
modulation treatment with subsequent resolution of symp-
toms [12]. Additive tests are required to establish the correct 
diagnosis of sensory CIDP: lumbar puncture, somatosen-
sory evoked potentials (SSEPs), magnetic resonance imag-
ings of the proximal portions of the cervico-brachial plexus 
and lumbosacral plexus, if necessary sural nerve or fibular 
nerve biopsies [13]. 
Two particular forms of sensory CIDP are described in 
scientific papers:
a) Clinical picture with distal, symmetrical, sometimes 
painful paraesthesia with a predominant onset of the soles 
or hands (feeling of socks tied to the talocrural joints, feel-
ing of sand between the toes and on the soles of the feet, 
sensation of invisible sandals on the feet) which then prog-
ress ascending to the level of the thighs. The neurological 
objective examination shows a thermo-algic hypoesthesia 
in socks and gloves, diminished or preserved deep tendon 
reflexes. Muscle strength according to Medical Research 
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Council (MRC) scale – 5 points in all limbs. Romberg sign 
is negative in all the patients [14]. 
b) Clinical picture of chronic, ataxic neuropathy asso-
ciated with distal paraesthesia. Ataxia manifests predomi-
nantly during walking with the presence of the positive 
Romberg sign and advanced self-perception disorders. 
A generalized areflexia is observed. NCS show the reduc-
tion in nerve conduction velocity across multiple trunks, 
increased distal motor latency and increased proximal F 
wave latency). Conductions blocks are uncommon, which 
explains the presence of normal muscle strength – 5 points 
in all muscle groups according to the MRC scale [15].
Material and methods
Two study groups were identified: 30 patients with typi-
cal CIDP and 30 patients with atypical CIDP according to 
the EFNS/PNS guideline (revised 2010). 
Clinical examination included the following scales: 
Overall Neuropathy Limitation Scale – (ONLS), INCAT 
sensory score, 9-hole peg test, 10 meters test, MRC scale 
[16,17]. NCS were performed in all the patients. A full 
routine biochemistry, electrophoresis and immunofixation 
of serum proteins, all spectrums of anti-myeline and anti-
ganglioside antibodies were performed. The proximal seg-
ments of the sensory peripheral nervous system can only be 
assessed by SSEPs [18]. SSEPs were considered to be sugges-
tive of proximal demyelination when they revealed: (i) a sig-
nificant increase in radicular conduction time with normal 
distal conduction time in at least 1 nerve and/or (ii) absence 
of N9/N18 potential or N13/N22 potential and/or delayed 
proximal volleys (N9 or N18) with normal distal conduc-
tion time in at least 2 nerves [19].
Cerebral spinal fluid (CSF) macroscopic/microscopic 
examination was performed in all the patients. Fibular nerve 
biopsies were obtained under local anesthesia from the lat-
eral and inferior part of the shank. 5 patients with typical 
CIDP and 4 patients with atypical CIDP underwent superfi-
cial peroneal nerve biopsies. The 5 centimeters long superfi-
cial peroneal nerve specimen was divided into three pieces: 
first piece was fixated in paraformaldehyde and stained with 
haematoxylin-eosin; second piece was fixated in glutaralde-
hyde and the subsequent generationof semi-thin sections 
were stained with toluidine blue; third piece was frozen in 
liquid nitrogen and stored at -80 degrees Celsius - for im-
munohistological research [20].
Semi-thin (0.5 μm) sections allow much greater resolu-
tion than that provided by specimens embedded in paraffin 
and allow accurate quantification of demyelination markers: 
the presence of onion bulbs, decreased number and density 
of large and small myelinated fibers, decreased thickness of 
the myelin sheath [21,22]. Statistical analysis was performed 
using statistical methods Mann-Whitney and Fisher (SPSS 
statistics 20). Cases with p ≤ 0.05 were considered statisti-
cally significant.
Results and discussion
The percentage of patients with atypical CIDP was the 
following: 10 patients with Lewis-Sumner syndrome rep-
resent 33% of patients with atypical CIDP, 6 patients with 
distal acquired demyelinating symmetric (DADS) poly-
neuropathy – 20% of patients and 14 patients with sensory 
CIDP – 47% of patients with atypical CIDP. Our results sug-
gest that sensory CIDP represents the most frequent form 
of atypical CIDP.
From the group of 14 patients with sensory CIDP – 4 
patients fulfilled the EFNS/PNS quideline 2010 criteria for 
NCS demyelination, 10 patients didn’t fulfill these criteria 
but instead were selected according to the criteria of the 
French Group of CIDP Experts [2].
The mean age of onset of the disease in the group of pa-
tients with sensory CIDP is 57.71 years. The clinical course 
of the disease is less disabling in sensory CIDP than in cases 
with typical CIDP. 14 patients were diagnosed with sensory 
CIDP, 10 patients had a monophasic disease course, 2 pa-
tients had evolution in relapses and remissions, and only 2 
patients presented progressive disease course. As compared 
to patients with typical CIDP forms: 6 cases with monopha-
sic evolution, 6 patients with relapsing and remitting disease 
courses and 18 patients had progressive evolution. 
Ataxia and numbness are the main symptoms of patients 
with sensory CIDP: all patients had numbness in the lower 
limbs and 7 patients had postural instability. No muscle 
weakness according to MRC scale was identified in sensory 
CIDP patients. In the group of patients with typical CIDP all 
patients had a predominant muscle weakness in the proxi-
mal regions of upper and lower limbs, postural instability 
had 24 from 30 patients with typical CIDP. Regarding posi-
tive sensory symptoms, feet constriction sensation predom-
inates in 5 out of 14 patients with sensory CIDP versus 4 out 
of 30 patients with typical CIDP (p <0.05). In 12 cases, pain 
was also described in addition to numbness. Deep tendon 
reflexes were diminished in 6 cases, in 3 cases only ankle 
jerk reflex was abolished, diffuse areflexia was observed in 
5 cases. 
Total ONLS in patients with sensory CIDP is equal to 
1.85 ± 0.21 points compared to total ONLS 4.17 ± 0.240 
points in patients with typical CIDP (p <0.001). Patients 
with Lewis-Sumner forms of atypical CIDP and patients 
with typical CIDP have the longest time of fulfilling the 
9-hole peg test (fig. 1). This means that functional ability of 
Fig. 1.  The average values of functional assays in atypical CIDP 
subtypes compared to average values in typical CIDP.
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their upper limbs is more affected than the functional ability 
of lower limbs. Also patients with DADS forms of atypical 
CIDP and patients with typical CIDP have the longest time 
of fulfilling the 10 meters test (fig. 1). It means that walk-
ing is most affected in this group of patients. Patients with 
sensory CIDP are less affected and have better prognosis of 
preserving their functional abilities.
According to NCS results presented in fig. 2, 3 – distal 
motor latencies, motor conduction velocities, proximal mo-
tor amplitudes, F waves latencies of median, ulnar, peroneal 
and tibial nerves are more preserved in atypical CIDP than 
in typical CIDP (p <0.001). These data suggest a less demy-
elinating and degenerative process in atypical CIDP patients 
compared with typical cases of CIDP.
Fig. 2.  Median values of distal motor latency (DML)  
in typical and atypical CIDP.
Fig. 3.  Median values of motor conduction velocities (MCV)  
in typical and atypical CIDP.
NCS in 14 cases with sensory CIDP show normal motor 
conduction velocity in 10 cases, and diminished only in 4 
cases. Also distal motor latency was diminished in 4 cases. 
Conduction block was present only in one case of sensory 
CIDP. Sensory conduction velocities in median and sural 
nerves were diminished in 6 cases. The amplitudes of the 
sensory nerve actions potentials (SNAP) in sural nerves 
were absolutely normal in 7 patients out of 14 with sensory 
CIDP (50% of patients with sensitive PDIC). From these 7 
patients 6 out of them (43%) have so-called inverse ratio – 
amplitude of the sural nerve SNAP is greater than the am-
plitude of median nerve SNAP, which is an important sup-
portive criteria for diagnosis of CIDP (fig. 4).
Fig. 4.  MCV – motor conduction velocity (m/s), SCV – sensory 
conduction velocity, DL – motor distal latency (ms),  
CB – conduction block, FL – F-wave latency (ms),  
SNAP – sensory nerve action potential.
NCS show no evidence of demyelinating criteria for 10 
patients with sensory CIDP, but these patients show clinical 
examination abnormalities that are not typical for chronic 
axonal polyneuropathies like: ataxia, generalized areflexia, 
distal hypoesthesia progressing toward the proximal por-
tions of the limbs. Therefore, the SSEPs investigation was 
performed to demonstrate proximal demyelination, at pre- 
or post-ganglion levels, levels that are not accessible for the 
conventional NCS [23]. SSEP examinations were done in 10 
patients diagnosed with sensory CIDP but with no signs of 
demyelination on NCS and compared with SSEP results of 
10 patients with typical CIDP. 6 patients with sensory CIDP 
had prolonged radicular conduction time in at least 1 limb 
compared to 7 patients in typical CIDP (p>0.05), and 7 had 
abnormal/delayed N9/N18 potentials and/or absent spinal 
potential in at least 1 limb compared to 8 patients with typi-
cal CIDP (p>0.05). In summary, all patients with sensory 
CIDP had evidence of proximal demyelination on SSEPs 
with no statistical difference from the patients with typical 
CIDP.
CSF protein was elevated in 10 patients, ranging from 0.5-
1.9 g/l, and normal in 4 cases. Data from our study are simi-
lar to the results of the French study [24]. CSF protein level 
was increased in 16 out of 22 patients with sensory CIDP 
(73% of patients studied) compared to 71% in our study. 
Fig. 5.  Semi-thin transversal section of peroneal superficial 
nerve showing onion bulb formation in a patient with sensory 
CIDP.
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Nerve biopsy findings were the following: reduction in 
myelinated fiber density was most frequent (100%), fol-
lowed by demyelination (90%), inflammation (44%), and 
onion bulb formation (55%). Endoneurial inflammation 
was more frequent in the relapsing-remitting form (fig. 5).
Conclusions
1.  NCS is the most important test used to diagnose de-
myelinating polyneuropathies. However, NCS are normal 
when demyelinating lesions are distributed proximally. This 
may lead to misdiagnosis or mismanagement.
2.  SSEPs should be carried out in all cases of atypical 
sensory polyneuropathy (accompanied by ataxia, areflexia) 
to demonstrate the proximal demyelination (at pre- or post-
ganglionic levels) not accessible for conventional NCS.
3.  ONLS and 9 whole peg tests are efficient to evaluate 
the level of disability in patients with CIDP. According to 
ONLS scale, patients with typical CIDP are more impaired 
than sensory atypical CIDP patients.
4.  Fibular nerve biopsy is performed only if the NCS 
don’t bring any demyelinating findings, but the clinical evo-
lution of the disease is progressive and disabling.
5.  There is significant phenotypic variability in the clini-
cal spectrum of CIDP suggesting that there are different im-
munopathological mechanisms at play. Future research is 
needed to identify disease markers.
6. NCS is not a sensitive test to diagnose sensory CIDP, 
in 70% of cases motor conduction velocities were not af-
fected. 
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